Management have been making A1 choices. They seem to have the talent and the ability to execute right through to the stage of deals with "big pharma". Some couldn't bake a loaf of bread. Good recovery in price from late 18 and looks to becoming into some vital stages which they seem ready to handle and push through.
Add to My Watchlist
What is My Watchlist?